Abstracts tagged "Clinical Response"

Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting
Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Dalton Sholter¹, Proton Rahman², Maqbool Sheriff³, Michel Zummer⁴, Suneil Kapur⁵, Philip Baer⁶, Michael Starr⁷, John Kelsall⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Brendan Osborne¹¹, Karina Maslova¹², Cathy Tkaczyk¹¹, Francois Nantel¹³ and Allen J Lehman¹², ¹University of Alberta, Edmonton, AB, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
Abstract Number: 2354 • 2016 ACR/ARHP Annual Meeting
Pharmaceutical Grade Chondroitin Sulfate Improves Knee Osteoarthritis Symptoms More Than Placebo and As Much As Celecoxib: Results of the Chondroitin Vs Celecoxib Vs Placebo Trial (CONCEPT)
J-Y Reginster and CONCEPT Authors' Group, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
Background/Purpose: For the assessment of Symptomatic Slow Acting Drugs in Osteoarthritis (SYSADOAs), regulatory Agencies request the assessment of two co-primary endpoints: pain and function. They…
Abstract Number: 2385 • 2016 ACR/ARHP Annual Meeting
Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients
Megha Sawhney¹, Gina A. Montealegre Sanchez², Robert Wesley³, Kost Bahar¹ and Raphaela Goldbach-Mansky⁴, ¹NIAMS, National Institutes of Health, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: CANDLE and SAVI are two rare autoinflammatory interferonopathies without validated outcome measures to assess disease activity; however, daily diaries of prominent disease symptoms have…
Abstract Number: 2481 • 2016 ACR/ARHP Annual Meeting
Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Teresa Jurado¹, Chamaida Plasencia-Rodriguez², Ana Martínez³, Victoria Navarro-Compán⁴, Eva Olariaga-Merida⁵, Diana Peiteado⁶, Alejandro Villalba⁶, Gema Bonilla⁶, Cristina Diego⁷, Alejandro Balsa² and Dora Pascual-Salcedo⁸, ¹Immunology, University Hospital La Paz, Madrid, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁴Rheumatology, University Hospital La Paz, Madrid, Spain, ⁵Immunlogy, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁷Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ⁸Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain
Background/Purpose: The anti-TNF monoclonal antibody Infliximab (Ifx), has proven effective in treating rheumatoid arthritis (RA), although in 40% of cases may fail, mainly due to…
Abstract Number: 2538 • 2016 ACR/ARHP Annual Meeting
Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis
Christopher J. Swearingen, Jessica Poon, Hannah Bernstein and Yusuf Yazici, Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
J. Antonio Avina-Zubieta¹, Andrew Chow², Philip Baer³, John Kelsall⁴, Proton Rahman⁵, Jacqueline Stewart⁶, Boulos Haraoui⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Francois Nantel¹¹, Karina Maslova¹², Cathy Tkaczyk¹³, Brendan Osborne¹³ and Allen J Lehman¹², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Independent Rheumatology Practice, Scarborough, ON, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Montreal, Montreal, QC, Canada, ⁸Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Hironari Hanaoka¹, Hidehiro Yamada², Tomofumi Kiyokawa³, Harunobu Iida¹, Takeshi Suzuki¹, Yoshioki Yamasaki⁴, Seido Ooka⁵, Hiroko Nagafuchi³, Takahiro Okazaki³, Daisuke Ichikawa⁶, Sayuri Shirai⁶, Yugo Shibagaki⁷, Junki Koike⁸ and Shoichi Ozaki³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, ⁸Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
Abstract Number: 2920 • 2016 ACR/ARHP Annual Meeting
The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis
Maaike Boonstra¹, Annemarie L. Dorjée¹, Koen D. Quint², Tom W.J. Huizinga¹, Hans U. Scherer³ and Jeska K. de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Dermatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Open-label studies provided evidence for possible efficacy of rituximab (RTX) in systemic sclerosis (SSc). Previously, we reported on a randomized placebo-controlled clinical trial in…
Abstract Number: 300 • 2016 ACR/ARHP Annual Meeting
Mindfulness Predicts Treatment Response from Non-Pharmacological Therapy in Knee Osteoarthritis
Augustine Lee¹, Lori Lyn Price², Xingyi Han³, Mei Chung⁴, William F. Harvey¹, Jeffrey Driban⁵, Timothy E. McAlindon⁶ and Chenchen Wang¹, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Clinical Care Research, Tufts Medical Center, Boston, MA, ³Public Health and Community Medicine, Tufts University, Boston, MA, ⁴Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, ⁵Tufts Medical Center, Boston, MA, ⁶Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Mindfulness is the ability to maintain a heightened awareness of one's moment-to-moment experiences without judging or reacting. Recent evidence suggests that mindfulness may improve…
Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting
Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis
Laura Kuusalo^1,2, Hannu Kautiainen³, Tuulikki Sokka-Isler⁴, Toini Uutela⁵, Laura Pirilä², Timo Yli-Kerttula⁶, Markku J Kauppi^7,8, Tuomas Rannio⁹, Kirsi Paalanen¹⁰, Arto Kokko⁹, Juha Asikainen⁹, Jelena Borodina¹⁰, Johanna Paltta², Kari Laiho¹¹, Andrus Mullanmaa¹², Kari Puolakka¹² and SandRA Study Group, ¹University of Turku, Turku, Finland, ²Turku University Hospital, Turku, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Lapland Central Hospital, Rovaniemi, Finland, ⁶Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁷School of Medicine, University of Tampere, Tampere, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹⁰Jyvaskyla Central Hospital, Jyvaskyla, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland, ¹²South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting
The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)
Sonia Lagacé¹, Louis Bessette^2,3, Louis Coupal⁴ and Denis Choquette⁴, ¹Medicine, Laval University, Quebec, QC, Canada, ²Rheumatology, Laval University, Québec, QC, Canada, ³Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Ronald F. van Vollenhoven¹, William Stohl², Richard Furie³, Norma Lynn Fox⁴, James Groark⁵, Damon Bass⁵, Milena Kurtinecz⁵, Bonnie Pobiner⁶, William Eastman⁶, Tania Gonzalez-Rivera⁵ and David Gordon⁵, ¹Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴GSK, Potomac, MD, ⁵GSK, Philadelphia, PA, ⁶GSK, Research Triangle Park, NC
Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…
Abstract Number: 475 • 2015 ACR/ARHP Annual Meeting
Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
Arthur Kavanaugh¹, Carol J. Etzel^2,3, Wendi Malley³, Chitra Karki³, Jeffrey D. Greenberg^3,4, Yanjun Bao⁵, Naijun Chen⁵ and Vishvas Garg⁶, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴NYU School of Medicine, New York, NY, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie, North Chicago, IL
Background/Purpose: Based on international task force recommendations, the primary goal of rheumatoid arthritis (RA) treatment is to: achieve control of symptoms to greatest extent possible,…
Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting
A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort
Jason Lee¹, VP Bykerk², George Dresser³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, J Carter Thorne², Diane Tin⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰ and CATCH Investigators, ¹Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Institut de Rhumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].